Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

[F-18] Fluciclovine (Axumin) PET/CT vs. [F-18] NaF PET/CT in the Evaluation of Prostate Cancer Osseous Metastatic Disease

Next Previous
X
Search
Trial Profile

[F-18] Fluciclovine (Axumin) PET/CT vs. [F-18] NaF PET/CT in the Evaluation of Prostate Cancer Osseous Metastatic Disease

Status: Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 06 Apr 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fluciclovine 18F (Primary) ; Sodium fluoride
  • Indications Bone metastases; Prostate cancer
  • Focus Diagnostic use; Pharmacokinetics

    • Most Recent Events

    • 21 Mar 2022 Planned End Date changed from 1 Dec 2023 to 18 Mar 2022.
    • 21 Mar 2022 Planned primary completion date changed from 1 Nov 2023 to 18 Mar 2022.
    • 21 Mar 2022 Planned initiation date changed from 1 Jun 2022 to 25 Mar 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top